Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib in Indolent Systemic Mastocytosis
NCT03731260Phase 2Active, not recruiting
- Sponsor
- Blueprint Medicines
- Start
- Apr 2019
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of avapritinib in indolent systemic mastocytosis (ISM) (7 arms), sponsored by Blueprint Medicines. Primary endpoints: Recommended Phase 2 dose at 9 months, Mean change in ISM Symptom Assessment Form total symptom score at 6 months and 1 more. Started Apr 2019; status: active, not recruiting.
02
Drugs
avapritinib
03
Conditions
indolent systemic mastocytosis (ISM)
Beyond the preview
Go deeper on NCT03731260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731260.